Healthcare Industry News: Trileptal
News Release - September 8, 2006
Taro Announces Filing Of ANDA For Oxcarbazepine Tablets 150, 300 And 600 MG
HAWTHORNE, N.Y.--(HSMN NewsFeed)--Sept. 8, 2006--Taro Pharmaceutical Industries Ltd. ("Taro," NASDAQ: TARO) today reported that it has filed an Abbreviated New Drug Application ("ANDA") with the U.S. Food and Drug Administration for Oxcarbazepine Tablets 150, 300 and 600 mg ("oxcarbazepine tablets").Oxcarbazepine tablets, currently marketed by Novartis as Trileptal® (oxcarbazepine) Tablets, are a prescription pharmaceutical product used in treating seizures. Taro's ANDA includes a "Paragraph IV" certification challenging Novartis' patent protection on Trileptal®. Under the process created by the Hatch-Waxman Act, Taro has notified Novartis of its patent challenge. Novartis, in turn, has initiated a lawsuit against Taro, which is a standard practice in Paragraph IV patent challenges.
Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products.
For further information, please visit www.taro.com.
Source: Taro Pharmaceutical
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!